This website is intended for healthcare professionals only.

Newsletter          
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Study finds vitamin D status and COVID-19 diagnosis shows inconsistent associations

Rod Tucker
14 June, 2022  

A large study revealed no consistent associations between vitamin D status and COVID-19 outcomes such as infection, hospitalisation and death

There are inconsistent associations between vitamin D status and the diagnosis of COVID-19, hospitalisations and mortality according to the findings of a large cohort study by researchers from Faculty of Epidemiology & Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Vitamin D is essential for bone health such that prolonged and severe vitamin D deficiency gives rise to rickets in children and osteomalacia in adults. Furthermore, vitamin D is an immune system modulator that induces an increase in antimicrobial proteins and activity against pathogens. In a systemic review of studies, it was found that supplementation with vitamin D results in a small reduction in the risk of acute respiratory infections although the role of vitamin D in COVID-19 remains uncertain. In a 2021 Cochrane review, the authors concluded that there is currently insufficient evidence to determine the benefits and harms of vitamin D supplementation as a treatment of COVID-19. But if vitamin D status and in particular, a deficiency of the vitamin, is associated with COVID-19, the use of supplements could be a valuable health intervention. As a result, for the present study, the UK team set out to examine the association between vitamin D status and several COVID-19 outcomes including infection, hospitalisation and death. They used data held within the UK Biobank and included individuals for whom at least one serum vitamin D test was available. Levels were recorded as deficient (< 25 nmol/L), insufficient (25 – 49 nmol/L) and sufficient ( > 50 nmol/L) and the primary outcome of interest was a laboratory confirmed infection with COVID-19. For their secondary outcomes, the team examined hospitalisation and mortality due to infection with the virus. The team also considered the risk of being diagnosed with COVID-19 when the vitamin D status was assessed, i.e., during the summer and winter months and used the definition of vitamin D sufficiency as the reference point. The analysis was performed using logistic regression after adjustment for covariates which included demographics, body mass index, smoking status and ethnicity.

Vitamin D status and COVID-19 outcomes

A total of 307, 512 individuals were included in the analysis of whom, 46% were deemed to vitamin D sufficient, 41% insufficient and 12% deficient. A total of 10,165 people became infected with COVID-19 with 51.4% of infections reported during autumn, 31% in the winter and only 3.8% in the summer.

Interestingly, during the summer months, participants who were vitamin D deficient had a 14% lower risk of being diagnosed with COVID-19 compared to those who were vitamin D sufficient (Hazard ratio, HR = 0.86, 95% CI 0.77 – 0.95, p < 0.01). In contrast, during the non-summertime months, the risk of becoming infected with COVID-19 was 14% higher among those who were vitamin D deficient (HR = 1.14, 95% CI 1.01 – 1.30, p = 0.04). However, there were no significant associations for individuals deemed vitamin D insufficient irrespective of the time of year.

With respect to COVID-19-related hospitalisations, compared to those who were vitamin D sufficient, there was no evidence that any other vitamin D status significantly affected the risk. Similarly, there was no evidence that the risk of COVID-19 mortality was affected by vitamin D levels.

In their conclusion the authors reported that there were inconsistent associations between vitamin D status and a diagnosis of COVID-19 and no clear association between vitamin D levels and either hospitalisation or death.

Citation
Lin LY et al. The association between vitamin D status and COVID-19 in England: A cohort study using UK Biobank PLoS One 2022